Wegovy Injections: What You're Actually Deciding

Do Wegovy injections suit your situation, or would a different treatment fit better?

This is usually the real decision. Wegovy is licensed for adults in the UK with a BMI of 30 or above, or 27 to 29.9 with at least one qualifying weight-related condition such as high blood pressure, type 2 diabetes, high cholesterol or obstructive sleep apnoea. Lower BMI thresholds apply for some ethnic backgrounds under UK clinical guidance. So the starting point is whether you meet the licensed criteria, and that is something a prescriber establishes through a proper clinical assessment, not a checklist you complete on your own.

Beyond eligibility, the next fork in the road is whether a weekly injection suits you at all. Some people find a pen straightforward from the first dose; others feel genuine anxiety about self-injecting and do better starting with oral semaglutide. The MHRA approved Wegovy tablets as the UK's first oral GLP-1 weight-management medicine in June 2026, which changed the conversation for people who had ruled injections out. If you are weighing both routes, our page on weight-loss treatment options sets out the differences plainly.

There is also the matter of which injectable treatment to consider. Semaglutide targets one gut-hormone receptor; tirzepatide targets two. The semaglutide injection page covers the mechanism in more depth if you want to understand how that distinction plays out in practice before speaking to a prescriber.

What the injection itself involves, routine, sites, and the fridge

A Wegovy pen is a single pre-filled device, used once a week, injecting into the fatty tissue just under the skin of your abdomen, outer thigh, or upper arm. The sites should be rotated so the same spot is not used week after week. The needle is short and fine; most people describe the sensation as mild once they have done it a handful of times.

Storage matters. Wegovy pens are kept in the fridge at 2 to 8°C, and the exact window for keeping them at room temperature before use is set out in the Patient Information Leaflet that comes with your treatment, always follow that rather than any general advice online. If you are planning to travel, it is worth reading the guidance on Wegovy storage and shelf life well before you go, not the morning of your flight. A sharps container is needed for safe disposal of used pens, this is a legal requirement in the UK, and your local pharmacy or council can advise on collection.

People also ask how many doses a pen contains. Unlike Mounjaro, where one KwikPen holds four weekly doses, each Wegovy pen is a single dose, so you use one pen per week. That is worth knowing before you plan storage space or calculate how many pens a month's supply requires.

Side effects: what tends to happen and when to get medical help

The most commonly reported side effects of Wegovy injections are gastrointestinal: nausea, vomiting, diarrhoea, constipation, burping and reflux. These are typically most noticeable in the first few weeks after starting or after a dose increase, and they settle for most people as the body adjusts. Fatigue, headache, dizziness and injection-site reactions also appear in the trial data.

The NHS medicines page for semaglutide is the clearest patient-level resource for the full side-effect picture, and the NHS semaglutide guidance is worth reading before you start. Serious effects are less common but matter: in January 2026, the MHRA issued a Drug Safety Update highlighting acute pancreatitis as an infrequent but potentially serious risk with GLP-1 medicines. If you develop severe stomach pain that extends towards your back (with or without vomiting) get urgent medical attention. Other signs that need prompt review include symptoms of gallbladder problems, signs of a serious allergic reaction, or significant low mood.

You can report any suspected side effect through the MHRA's Yellow Card scheme at yellowcard.mhra.gov.uk. It is open to patients as well as healthcare professionals, and reports contribute to the ongoing safety monitoring of all licensed medicines.

Wegovy injections are not suitable during pregnancy, while breastfeeding, or when trying to conceive. They are not licensed for under-18s. Anyone with a history of medullary thyroid carcinoma, pancreatitis, or certain other conditions needs to discuss those with their prescriber before starting.

Getting Wegovy injections in the UK, NHS, private, and what to check

On the NHS, Wegovy is available through specialist weight management services under NICE guidance (TA875), which recommends it for adults with a BMI of 35 or above alongside at least one weight-related condition, and only within a specialist multidisciplinary programme for a maximum of two years. Waiting lists for those services are often substantial, and not everyone meets the threshold.

Private treatment through a regulated online pharmacy is the alternative. If you are researching costs, our Wegovy price comparison page sets out what private treatment typically involves and what different providers include in their headline figure, consultation fees, prescription costs and aftercare support vary considerably, and the differences are worth understanding.

Whatever route you take, the most important check is whether the pharmacy is registered with the GPhC. You can verify any online pharmacy at pharmacyregulation.org/registers. Wegovy is a prescription-only medicine, and any seller offering it without a prescription is not operating legally, and the MHRA has confirmed counterfeit pens have reached patients through unregulated online sellers.

If you are ready to talk through your own situation, starting a free consultation with our prescribers is the natural next step. Consultations at nume are reviewed the same day by a GPhC-registered Independent Prescriber, a real clinician reads your answers, not automated software.